Upstream Bio, Inc. (UPB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Upstream Bio, Inc. (UPB) has a cash flow conversion efficiency ratio of -0.131x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.62 Million) by net assets ($270.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Upstream Bio, Inc. (UPB) market capitalisation for the company's overall valuation and market capitalisation.
Upstream Bio, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Upstream Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Upstream Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Upstream Bio, Inc. ranked by their cash flow conversion efficiency. See Upstream Bio, Inc. cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
0.014x |
|
Modern Avenue Group Co Ltd
SHE:002656
|
-0.393x |
|
Okins Electronics Co. Ltd
KQ:080580
|
0.113x |
|
Weifu High Tech Group
SHE:200581
|
0.049x |
|
Xiangyang BOYA Precision Industrial Equipments Co. Ltd
SHE:300971
|
0.044x |
|
LiveWire Group Inc.
NYSE:LVWR
|
-0.459x |
|
Jiangsu Lanfeng Bio-chemical Co Ltd
SHE:002513
|
-0.330x |
|
Text S.A.
WAR:TXT
|
0.303x |
Annual Cash Flow Conversion Efficiency for Upstream Bio, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Upstream Bio, Inc. from 2022 to 2025. View Upstream Bio, Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $339.77 Million | $-133.28 Million | -0.392x | -211.46% |
| 2024-12-31 | $469.85 Million | $-59.17 Million | -0.126x | -140.89% |
| 2023-12-31 | $-123.13 Million | $-37.93 Million | 0.308x | +71.91% |
| 2022-12-31 | $-106.16 Million | $-19.02 Million | 0.179x | -- |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.… Read more